AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
With this milestone, Contraline’s global patent portfolio, including those owned and licensed, has grown to 15 issued patents and more than 50 pending applications across the United States, Europe, Australia, Canada, and Asia. Contraline’s flagship product is the ADAM™ hydrogel, a biocompatible hydrogel implanted in the vas deferens designed to block sperm transport. The IP portfolio spans the entire innovation lifecycle of hydrogel-based vas-occlusive contraception, from novel biomaterials and precision delivery systems to advanced imaging and minimally-invasive reversal techniques.
“This milestone underscores our commitment to leading innovation in male contraception,” said Kevin Eisenfrats, Co-Founder and CEO of Contraline. “Our goal has always been to deliver the best possible experience for patients and physicians. Every new patent represents years of R&D and our belief that the ADAM™ hydrogel can redefine the landscape of birth control for men.”
Contraline’s issued and pending patents protect multiple critical components of its technology platform:
Hydrogel Compositions
Contraline has multiple issued patents that protect a range of hydrogel systems with tunable pore sizes and chemical and mechanical properties designed for safe, effective, and reversible sperm occlusion. These patents include, but are not limited to, two-component hydrogel compositions, which can be mixed in situ to rapidly form a stable, occlusive implant within the vas deferens.
Delivery Systems
Multiple patents cover proprietary injection devices featuring precision-controlled drive mechanisms, methods of delivery, and kit configurations that ensure consistent, in-office administration of the ADAM™ hydrogel.
Reversal Methods
Patents that cover a range of techniques for restoring fertility, including external stimuli that degrade or dissolve the hydrogel implant in situ.
Contraline’s patent estate includes issued patents across Europe, Canada, Australia, and Japan, with pending applications in all major international markets.
While Contraline’s core focus is male contraception, its underlying hydrogel platform could support broader applications—including reversible occlusion of other anatomical lumens, such as the fallopian tubes, and use in therapeutic drug delivery or vascular modulation.
With 15 issued patents and a rapidly expanding pipeline of pending claims, Contraline has established itself as a clear IP leader in biomaterials-based contraception.
About Contraline, Inc.
Contraline, Inc. is a venture-backed, clinical-stage, biotechnology company focused on innovation in reproductive health. The company’s mission is to develop novel male contraceptives that are safe, effective, appealing, and reversible. Visit www.contraline.com
Disclaimer ADAM™
The ADAM™ device is an investigational device and is not yet authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory authority worldwide. As such, the ADAM™ device is not available for commercial use at this time and it is currently available only for investigational use in approved clinical trials.
Kevin Eisenfrats
Contraline, Inc.
email us here
Visit us on social media:
LinkedIn
Instagram
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
